Clinical Trial Update: CONTAK RENEWAL 3 AVT [Phase 3]

View source ↗

Summary

Phase 3 clinical trial CONTAK RENEWAL 3 AVT by Boston Scientific has completed. The study investigated effects in heart failure and atrial fibrillation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Heart Failure

Drugs mentioned

• CONTAK RENEWAL 3 AVT

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Heart Failure, Atrial Fibrillation | Phase 3 | Status: COMPLETED